{
    "nct_id": "NCT04017546",
    "official_title": "A Phase I Combination Study of CYC065 and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes",
    "inclusion_criteria": "* Previously treated AML or MDS based on WHO classification and having at least 10% blasts in peripheral blood\n* ECOG 0-2\n* Adequate renal function\n* Adequate liver function\n* INR <=1.2 in patients not receiving chronic anticoagulation\n* At least 2 weeks from prior cytotoxic chemotherapy, radiation therapy, major surgery or other investigational cancer therapy\n* Agree to practice effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* AML is of the subtype of APL or extramedullary myeloid tumor without bone marrow involvment\n* Known AML involvement in CNS that is symptomatic and active\n* Currently receiving radiotherapy, biological therapy, or any other investigational agents\n* Uncontrolled intercurrent illness\n* Pregnant or lactating\n* Known to be HIV-positive\n* Known active hepatitis B and/or hepatitis C infection",
    "miscellaneous_criteria": ""
}